Tech Company Financing Transactions
Protiva Biotherapeutics Funding Round
BDC Venture Capital, Growthworks Capital and Kinetic Ventures joined a $3 million funding round for Protiva Biotherapeutics. The round was announced on 7/5/2007.
Transaction Overview
Company Name
Announced On
7/5/2007
Transaction Type
Debt
Amount
$3,000,000
Round
Undisclosed
Proceeds Purpose
Mark J. Murray, Protiva's President and Chief Executive Officer said, "We are well positioned to continue advancing the development of new therapeutic products and business alliances.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
3480 Gilmore Way 100
Burnaby BC, V5G 4W7
Canada
Burnaby BC, V5G 4W7
Canada
Phone
Website
Email Address
Overview
Protiva Biotherapeutics is a development stage biotechnology company, focused on pharmaceutical products to fight against cancer, metabolic and infectious disease. Protiva's technology, employing lipid nanoparticles to encapsulate and deliver nucleic acid based drugs, such as siRNA, allows for the development of molecular therapeutics that act selectively at sites of disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Murray
Browse more venture capital transactions:
Prev: 7/5/2007: Vanu venture capital transaction
Next: 7/5/2007: Verified Person venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs